Delivery Order SPE2DB20D1047-SPE2DB25FF83Y
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency has awarded a delivery order valued at $6,837.84 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens. The award, issued on July 30, 2025, represents a firm fixed price delivery order with an ultimate completion date of July 31, 2025, and carries no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $7,656.84 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on August 18, 2025, with completion scheduled for August 19, 2025. This non-set-aside, competitively awarded contract operates under a firm fixed price arrangement and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $34,670.48 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on July 30, 2025, with completion scheduled for July 31, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded contract leveraging AmerisourceBergen's established pharmaceutical distribution capabilities. The contract is executed under the company's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $13,253.95 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 mL pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child action under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $66,205.05 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL pens on September 11, 2025, with a completion date of September 12, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a single delivery order issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,128.38 for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $8,322.75. This firm fixed price delivery order, which is set to be completed by August 28, 2025, will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a non-set-aside, competitively awarded contract issued under AmerisourceBergen's existing pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Dupixent 300 mg/2 mL pens totaling $20,114.60 with completion scheduled for July 22, 2025. This competitive, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $11,340.32 on September 9, 2025, for the supply of Dupixent 300 mg/2 mL pens. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 10, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- SPE2DB20D1047Indefinite Delivery Contract
- SPE2DB20D1047-SPE2DB25FF83YDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $31,746.06 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on September 12, 2025, with a completion date of September 15, 2025. This firm fixed-price delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 and extends through December 2026. The contract does not utilize a set-aside designation and was awarded competitively. Performance will be executed from AmerisourceBergen's Conshohocken, Pennsylvania location. This delivery order represents a single transaction within AmerisourceBergen's comprehensive pharmaceutical supply agreement with the Defense Logistics Agency, which enables the company to distribute a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The Dupixent (dupilumab) product being supplied is a prescription biologic medication used to treat conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis. AmerisourceBergen's role as a prime vendor through the DLA Medical Supply Chain demonstrates the company's established capability to fulfill federal pharmaceutical procurement requirements, with similar delivery orders spanning multiple therapeutic domains including specialty medications, vaccines, and medical devices for Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $31.7k | 9/12/25 |